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The growing appreciation of the active
interface between the immune system
and the nervous system includes recog-
nition of the cell surface molecules and
the transducing mechanisms that are
shared between the two systems. Per-
haps even more compelling is the identi-
fication of intercellular messengers that
mediate active signaling between the two
systems. Neurotransmitters and neu-
ropeptides, well known for their role in
the communication between neurons, are
also capable of activating monocytes and
macrophages and inducing chemotaxis in
immune cells. Transmitters and neu-
ropeptides released by local neuronal
processes are, therefore, well suited for
mediating the ability of neurons to par-
ticipate in inflammatory reactions at sites
of injury or infection, as discussed below.
In addition, immune tissues such as the
spleen and lymph nodes are innervated,
and pharmacological manipulations indi-
cate that transmitters and neuropeptides
are likely to regulate immune functions
(1, 2).
A different class of intercellular mes-
sengers is also likely to move in both
directions between these two organ sys-
tems. Cytokines, many of which have
been discovered in studies of the hema-
topoietic system, are well known to reg-
ulate immune development and function.
Many cytokines have the ability to reg-
ulate neural cell proliferation and gene
expression. Interleukin (IL) 1 and 2, y-in-
terferon, tumor necrosis factor a and f3,
and various members of the transforming
growth factor 83 superfamily are immu-
noregulatory cytokines that affect sur-
vival, growth, and gene expression of
various types of neurons and glia in cul-
ture. Moreover, several of these cyto-
kines are either normally expressed in the
nervous system or are up-regulated in the
central or peripheral nervous system af-
ter injury or neurological disease. These
findings indicate that a given cytokine
could mediate "cross-talk" between the
nervous and immune systems, in both
directions.
Another, recently recognized and un-
usual cytokine family may play such a
role. Results from overexpression stud-
ies presented in this issue and elsewhere
(15, 45-48) and results from gene target-
ing experiments in mice (19, 44, 49) con-
firm that one of the members of this
family, leukemia inhibitory factor (LIF),
can regulate hematopoiesis and T-cell
maturation, as well as neuronal survival
and gene expression. The role of LIF in
the interface between the two systems is
particularly striking in inflammation. LIF
is increased in a variety of inflammatory
conditions, is produced by immune cell
lines and primary glial cells, and is re-
quired for neurons to respond to injury.
LIF, IL-6, IL-11, ciliary neurotrophic
factor (CNTF), growth promoting activ-
ity, and oncostatin M belong to an un-
usual family of proteins termed the neu-
ropoietic cytokines (3-5). The unique as-
pect of this group of proteins is that
although they share only very limited
sequence homology, they exert very sim-
ilar effects on a variety of tissues. Several
of these proteins can, for instance, in-
duce the same set of acute-phase re-
sponse proteins in liver, support the self
renewal of cultured embryonic stem
cells, inhibit lipogenesis, and enhance the
survival of cultured motor neurons (see
ref. 6). Despite their limited homology,
the neuropoietic cytokines are predicted
to share a four antiparallel helix bundle
secondary structure (7, 8), a prediction
that is borne out by the recent structure
determination of CNTF (N. McDonald,
personal communication). These ligands
of very similar structure bind to receptor
subunits that share various degrees of
homology (9, 10). The receptor com-
plexes also contain an identical signal
transducing subunit, gpl30 (11), that
leads to the induction of similar phos-
phorylation cascades by these cytokines
(12-14). The overlaps in receptors and
signal cascades offer a convenient mo-
lecular explanation for the often redun-
dant biological activities of the neuropoi-
etic cytokines.
Nervous System. Although extensively
characterized in culture, much less is
known about the effects of this cytokine
family on the nervous system in vivo. In
this issue, Bamber et al. (15) use the
insulin promoter to induce ectopic ex-
pression of LIF in the pancreas and find
that the normally noradrenergic sympa-
thetic neurons that innervate this tissue
switch transmitter phenotypes to become
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cholinergic. This result provides striking
in vivo confirmation of early culture re-
sults with postmitotic sympathetic neu-
rons, initially using conditioned medium
and then pure LIF (called cholinergic
differentiation factor in that body of
work) (16-18). LIF does not, however,
appear to be the cholinergic factor that is
known to act during the normal develop-
ment of sympathetic neurons innervating
the sweat glands (19). Those neurons
switch phenotype in response to a factor
that appears to be similar but not identi-
cal to CNTF (20, 21). In addition to
regulating neuronal gene expression, LIF
can also act as a survival factor for neu-
rons. When applied to peripheral nerves
in vivo, the cytokine is retrogradely
transported and rescues damaged sen-
sory neurons (22, 23), as it does in culture
(24). LIF also alters the phenotype of
sensory neurons in culture (25, 26). Ap-
plication of CNTF can prevent death of
thalamic and motor neurons in vivo, both
after lesion and during the normal cell
death period (27-29). Exogenous CNTF
also slows degeneration of motor neu-
rons in a mouse model of progressive
motor neuropathy (30) and induces
sprouting of motor axons in muscle (31).
While overexpression reveals some of
the capabilities ofthese cytokines in vivo,
it does not necessarily demonstrate the
normal roles of these proteins. For
CNTF, gene targeting has provided evi-
dence that this cytokine does not, in fact,
regulate motor neuron survival during
development. Rather, the results of the
knockout of the CNTF gene point to a
role for this protein in the maintenance of
healthy motor neurons in adulthood (32).
Null mutations in humans do not, how-
ever, lead to obvious motor symptoms
(33). Disruption of the LIF gene, in con-
trast, demonstrates a role for this cyto-
kine in neuronal response to injury. Prior
results had suggested LIF as a candidate
for mediating the induction of a set of
neuropeptides after nerve transection.
The model predicted that nerve section
causes enhanced production or release of
LIF, which could then act on neurons to
alter their neuropeptide gene expression.
While there was evidence that LIF can be
produced by glial cells in culture (16, 34),
recent Northern blot (35) and in situ
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analysis shows that Schwann cells can
dramatically up-regulate LIF expression
in response to peripheral nerve section
(36, 37). In addition, recombinant LIF
can duplicate the effects of nerve injury
in the induction of particular neuropep-
tides in sympathetic neurons (6, 37, 38).
In striking confirmation of this model,
when sympathetic nerves are cut in LIF-
mice, the neuropeptide induction is
greatly diminished compared to the neu-
ronal response in wild-type mice (19).
In contrast to the induction of LIF,
nerve transection in normal animals
causes CNTF mRNA and protein levels
in Schwann cells to drop (39-42). Thus,
these two cytokines, which have identi-
cal effects on many types of neurons, are
regulated in complimentary fashion in
peripheral nerve. Moreover, the knock-
out mice for these cytokines display com-
plimentary phenotypes that parallel those
distinct regulatory controls. CNTF is
high in normal Schwann cells and is re-
quired for maintenance of healthy motor
neurons in adults, while LIF is induced
by injury and is required for the neuronal
response to injury. Similar studies are
currently underway in the brain, where
LIF levels rise after injury (43) and LIF-
mice display abnormalities (44).
Hematopoietic System. LIF overex-
pression and gene disruption also affects
hematopoiesis. Injection of high levels of
LIF in mice results in elevated numbers
of splenic megakaryocytes and platelets,
loss ofbody fat, an acute phase response,
splenomegaly, excess and ectopic bone
formation, and gonadal dysgenesis (45-
47). Many of these results are consistent
with the known distribution of LIF re-
ceptors and with the effects of this cyto-
kine on cultured cells. An additional
more selective phenotype was obtained
by driving overexpression of LIF in T
cells. In this transgenic mouse line, the
thymus is strikingly deficient in
CD4+CD8' cells, being populated in-
stead by B cells. Lymph nodes, in con-
trast, contain a vastly expanded popula-
tion of CD4+CD8+ lymphocytes (48).
The profoundly disorganized thymic epi-
thelium in these mice, coupled with the
results of bone marrow transplants, sug-
gest that the apparent interconversion of
thymic and lymph node phenotypes is
due to disruption of stroma-lymphocyte
interactions. These results complement
those reported earlier for LIF knockout
mice. Although the LIF- mice display
apparently normal thymocyte cell popu-
lations, there is evidence of reduced my-
eloid progenitors and defective thymic
T-cell activation (49). Here too, bone
marrow transplantation studies indicated
that the defects in stem cell numbers and
T-cell activation are probably due to a
requirement for LIF expression in the
hematopoietic microenvironment. These
two mouse strains present an excellent
opportunity to investigate stromal influ-
ences in hematopoiesis, an area of study
that is relatively underdeveloped.
Interactions Between the Nervous and
Immune Systems. It is intriguing that LIF
levels have been found to be elevated in
various inflammatory conditions, includ-
ing rheumatoid arthritis, acute kidney
rejection, acute bronchoalveolar re-
sponse, and septic shock (refs. 50-52 and
T. Ulich, M.-J. Fann, P.H.P., J. Wil-
liams, B. Samal, J. del Castillo, S. Yin,
K. Guo, and D. Remick, unpublished
data). It is not entirely clear, however,
which cell types are responsible for LIF
secretion in each of these syndromes.
For nerve transection, cited above, glial
cells are at least a major contributor to
the induction of LIF mRNA (36). An
independent body ofwork has implicated
nerve cells in a "neurogenic" component
of inflammation. Denervation prior to the
experimental induction of inflammation
can result in a diminished inflammatory
response. Moreover, pharmacological ex-
periments implicate the release of trans-
mitter and neuropeptide from neuronal
endings as the active agents in this neu-
rogenic function. In experimental arthri-
tis, for instance, the levels of substance P
(SP) and calcitonin gene-related peptide
(CGRP) are increased in the sensory neu-
rons that innervate affected joints (53,
54). LIF in synovial fluid from patients
with osteoarthritis and rheumatoid arthri-
tis (55) could contribute to this cascade
by inducing SP and CGRP in sympathetic
neurons that do not normally express
them. These neuropeptides enhance
monocyte production of cytokines, such
as IL-6, tumor necrosis factor a, and
IL-1/3 (56-60). Moreover, SP is chemo-
tactic for monocytes and macrophages
(61, 62). Thus, there is a cycle of inter-
dependent reactions such that neuronal
gene expression is altered by injury and
inflammation, and the induced neuropep-
tides can actively participate in the in-
flammation event itself (51, 63, 64). A
further interesting complexity is that pe-
ripheral blood cells, such as megakaryo-
cytes and T cells, contain high levels of
neuropeptides such as neuropeptide Y
and enkephalin (65, 66).
Mast cells are also important in this
context. They are concentrated in partic-
ular locations in the central nervous sys-
tem (67-69), they can be found in close
association with axons in the peripheral
nervous system (70), and they contain
and release cytokines (including LIF),
neurotrophins, neuropeptides, and bio-
genic amines (71-75). Mast cells release
some of these agents when nerves near
them are stimulated (76). For instance,
SP from sensory nerves stimulates hista-
mine and serotonin release from mast
cells, which is one of the mechanisms
whereby mast cells participate in neu-
roinflammatory conditions (77-80). In
addition, the release of transmitters, neu-
ropeptides, and cytokines by mast cells
could modulate neuronal activity and
gene expression in a feedback loop.
While this brief commentary focuses
primarily on LIF, other cytokines are
also key agents in the interactions be-
tween the immune system and nervous
system. It seems likely that some of these
cytokines are involved in the type of
feedback cascades discussed for LIF. Of
particular interest in this context are ac-
tivin, bone morphogenetic protein 2 and
6, transforming growth factor (3, IL-1,
and y-interferon, which are cytokines
known to influence gene expression and
survival of peripheral neurons (5, 38,
81-88).
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